New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams’ dynamism and local potential.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
AMU, IPC, CRCM
The thrust of MI is the ability of Marseille researchers, clinicians and industrials to play as a team.